0574: Determinants and prognostic value of Galectin-3 in patients with aortic valve stenosis - the COFRASA-GENERAC study

详细信息    查看全文

• 作者：Dimitri Arangalage ; ^{dimi_ar@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Virginia Nguyen ; Tiphaine Robert ; Maria Melissopoulou ; Tiffany Mathieu ; Candice Estellat ; Isabelle Codogno ; Virginie Huart ; Xavier Duval ; Claire Cimadevilla ; Bernard Iung ; Monique Dehoux ; Alec Vahanian ; David Messika-Zeitoun
• 刊名：Archives of Cardiovascular Diseases Supplements
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：8
• 期：1
• 页码：59
• 全文大小：49 K

文摘

Identifying subgroups of asymptomatic patients with aortic stenosis (AS) who may benefit from early intervention is a critical challenge due to the risk of sudden death and irreversible myocardial dysfunction without preceding symptoms. In this study, we analyzed the determinants and prognostic value of Galectin-3 in a large cohort of patients with AS.

Methods

We included patients with at least mild degenerative AS enrolled in 2 ongoing prospective clinical studies, COFRASA and GENERAC, aiming at assessing the determinants of AS occurrence and progression.

Results

Between November 2006 and July 2013, 583 patients were prospectively enrolled. Severe AS was diagnosed in 312 (56%) patients among whom 220 (38%) were symptomatic. Age (p<0.0001) and reduced creatinine clearance (p<0.0001) were positively associated with Galectin-3 level.

No significant association was found between Galectin-3 and echocardio-graphic parameters of AS severity including aortic valve area (p=0.41), mean transvalvular gradient (p=0,27), and AS jet velocity (p=0.52). Galectin-3 did not provide diagnostic evidence of severe AS (area under the curve=0.53). Galectin-3 was not influenced by symptomatic status. Echocardiographic parameters of LV remodeling were not associated with Galectin-3 in multivariate analysis. Event-free survival analysis revealed no prognostic value of Galectin-3.

Conclusions

The main determinants of Galectin-3 level were age and renal function. There was no association between Galectin-3 and symptomatic status and echocardiographic parameters associated with LV remodeling. Galectin-3 didn’t provide prognostic information on the occurrence of AS related events. These results do not support the use of Galectin-3 in the decision making process of patients with AS.